Effects of SLCO1B1 Polymorphism and Pitavastatin on the Pharmacokinetics of Repaglinide in Chinese Healthy Volunteers.

Trial Profile

Effects of SLCO1B1 Polymorphism and Pitavastatin on the Pharmacokinetics of Repaglinide in Chinese Healthy Volunteers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Pitavastatin (Primary) ; Repaglinide (Primary)
  • Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Type 2 diabetes mellitus
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 21 May 2012 Actual end date changed from Feb 2009 to Nov 2009 as reported by Chinese Clinical Trial Register record.
    • 28 Dec 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry; ACTRN12611001254987).
    • 06 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top